The facility is expected to become operational by FY2028-29
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The innovative eyedrop targets inflammation and pain following ocular surgery
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Subscribe To Our Newsletter & Stay Updated